First Western Ship Transits Strait of Hormuz Since Iran War Began 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Apple Turns 50: From Garage Startup to AI Crossroads 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
IRVINE, Calif., July 27, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (Nasdaq:SVA). Investors who purchased or otherwise acquired shares between April 30, 2013 and May 16, 2017 inclusive (the “Class Period”), should contact the firm in advance of the September 1, 2017 lead plaintiff motion deadline.
If you purchased Sinovac shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
According to the Complaint, throughout the Class Period, Sinovac made false and/or misleading statements and/or failed to disclose: that Chairman and CEO Weidong Yin bribed a member of the Chinese Food and Drug Administration to assist Sinovac’s vaccine clinical trial and approval; that such conduct would subject the Company to heightened regulatory scrutiny; thus, Sinovac’s public statements were materially false and misleading at all relevant times. When this information reached the public, shares of Sinovac declined in value materially, which caused investors harm according to the Complaint.
If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
